DHR · News · 20261022N

End-Market Demand Trends

DANAHER CORP /DE/ · 2026-10-22 · Importance 22 · Surprise 32

Analysts cited improving demand in Danaher’s life sciences tools and diagnostics markets, while bioprocessing recovery remains a key investor concern. Stifel expects more than 5% organic growth driven by Cytiva, indicating improving biotechnology demand. Respiratory-related revenue pressures remain a challenge, tempering expectations for the Diagnostics business.